Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials
暂无分享,去创建一个
P. Serruys | R. D. de Winter | S. Cook | Takeshi Kimura | D. Capodanno | Y. Onuma | T. Asano | Y. Miyazaki | E. Tenekecioğlu | Y. Katagiri | C. Collet | R. Cavalcante | R. Gao | Y. Sotomi | S. Puricel | Rafael Cavalcante | Yosuke Miyazaki
[1] I. Penn,et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study) , 1998, European heart journal.
[2] Patrick W Serruys,et al. Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[3] P. Serruys,et al. Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents: A Prospective Cohort Study , 2012, Circulation.
[4] Patrick W Serruys,et al. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? , 2012, European heart journal.
[5] P. Serruys,et al. Very late scaffold thrombosis after bioresorbable scaffold implantation: an unexpected new enemy on the horizon… or just a false alarm? , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[6] Cynthia D Mulrow,et al. Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change , 2014, Annals of Internal Medicine.
[7] W. Cheong,et al. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. , 2015, Journal of the American College of Cardiology.
[8] Varesh Prasad,et al. Macro- and microscale variables regulate stent haemodynamics, fibrin deposition and thrombomodulin expression , 2014, Journal of The Royal Society Interface.
[9] F. Van de Werf,et al. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. , 1997, Circulation.
[10] Katja Jasinskaja,et al. Elaboration and Explanation ⋆ , 2011 .
[11] F. Eberli,et al. Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings. , 2015, Journal of the American College of Cardiology.
[12] W. Cheong,et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. , 2015, European heart journal.
[13] Ryo Torii,et al. The Nidus for Possible Thrombus Formation: Insight From the Microenvironment of Bioresorbable Vascular Scaffold. , 2016, JACC. Cardiovascular interventions.
[14] P. Teirstein,et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. , 2015, The New England journal of medicine.
[15] Hak Seung Lee,et al. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials. , 2016, JACC. Cardiovascular interventions.
[16] W. Cheong,et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis , 2016, The Lancet.
[17] Hiroki Shiomi,et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[18] G. Stone,et al. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.
[19] Baris Gencer,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .
[20] M. Togni,et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial. , 2017, International journal of cardiology.
[21] M. Togni,et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. , 2015, Journal of the American College of Cardiology.
[22] Bernard Chevalier,et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial , 2016, The Lancet.
[23] P. Serruys,et al. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. , 2016, JACC. Cardiovascular interventions.
[24] George F Borm,et al. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method , 2014, BMC Medical Research Methodology.
[25] D. Atar,et al. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .
[26] P. Teirstein,et al. Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study. , 2000, Circulation.
[27] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[28] B Meier,et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. , 1991, The New England journal of medicine.
[29] Heribert Schunkert,et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials , 2016, The Lancet.
[30] G. Stone,et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.
[31] P. Serruys,et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial , 2015, The Lancet.
[32] F. Verheugt,et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. , 2009, Journal of the American College of Cardiology.
[33] C. Di Mario,et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. , 2014, JACC. Cardiovascular interventions.
[34] A. Schmermund,et al. Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. , 2016, Journal of the American College of Cardiology.
[35] P. Shekelle,et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2015, BMJ : British Medical Journal.
[36] S. Cook,et al. Optical Coherence Tomography Findings in Bioresorbable Vascular Scaffolds Thrombosis , 2015, Circulation. Cardiovascular interventions.
[37] Patrick W Serruys,et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. , 2015, European heart journal.
[38] R. Whitbourn,et al. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Ev , 2014, JACC. Cardiovascular interventions.
[40] P. Serruys,et al. Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents , 2015, Circulation. Cardiovascular interventions.
[41] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[42] P. Serruys,et al. TCT-49 Two-year clinical outcome of Everolimus-eluting bioresorbable scaffold vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. , 2016, Journal of the American College of Cardiology.
[43] P. Serruys,et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial , 2015, European heart journal.